KR101504770B1 - 내성 항원에 대항하는 활성 항체의 생산 방법, 상기 방법에 의해 생산된 항체 및 이의 용도 - Google Patents

내성 항원에 대항하는 활성 항체의 생산 방법, 상기 방법에 의해 생산된 항체 및 이의 용도 Download PDF

Info

Publication number
KR101504770B1
KR101504770B1 KR1020097008469A KR20097008469A KR101504770B1 KR 101504770 B1 KR101504770 B1 KR 101504770B1 KR 1020097008469 A KR1020097008469 A KR 1020097008469A KR 20097008469 A KR20097008469 A KR 20097008469A KR 101504770 B1 KR101504770 B1 KR 101504770B1
Authority
KR
South Korea
Prior art keywords
tumor
antibody
seq
sequence
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097008469A
Other languages
English (en)
Korean (ko)
Other versions
KR20090057469A (ko
Inventor
릴리앙 꼬뜨쉬
알렉쌍드라 주앙느오
Original Assignee
피에르 파브르 메디카먼트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피에르 파브르 메디카먼트 filed Critical 피에르 파브르 메디카먼트
Publication of KR20090057469A publication Critical patent/KR20090057469A/ko
Application granted granted Critical
Publication of KR101504770B1 publication Critical patent/KR101504770B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020097008469A 2006-09-28 2007-09-27 내성 항원에 대항하는 활성 항체의 생산 방법, 상기 방법에 의해 생산된 항체 및 이의 용도 Expired - Fee Related KR101504770B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0608514A FR2906533B1 (fr) 2006-09-28 2006-09-28 Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
FR06/08514 2006-09-28
PCT/EP2007/060243 WO2008046724A1 (en) 2006-09-28 2007-09-27 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses

Publications (2)

Publication Number Publication Date
KR20090057469A KR20090057469A (ko) 2009-06-05
KR101504770B1 true KR101504770B1 (ko) 2015-03-20

Family

ID=38164542

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097008469A Expired - Fee Related KR101504770B1 (ko) 2006-09-28 2007-09-27 내성 항원에 대항하는 활성 항체의 생산 방법, 상기 방법에 의해 생산된 항체 및 이의 용도

Country Status (21)

Country Link
US (2) US8241646B2 (cg-RX-API-DMAC7.html)
EP (4) EP2497491B1 (cg-RX-API-DMAC7.html)
JP (1) JP5774276B2 (cg-RX-API-DMAC7.html)
KR (1) KR101504770B1 (cg-RX-API-DMAC7.html)
CN (1) CN101516394B (cg-RX-API-DMAC7.html)
AR (1) AR063061A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007312437C1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0717246A2 (cg-RX-API-DMAC7.html)
CA (1) CA2663561A1 (cg-RX-API-DMAC7.html)
FR (1) FR2906533B1 (cg-RX-API-DMAC7.html)
IL (1) IL197790A (cg-RX-API-DMAC7.html)
MA (1) MA30954B1 (cg-RX-API-DMAC7.html)
MX (1) MX2009003245A (cg-RX-API-DMAC7.html)
NO (1) NO20091613L (cg-RX-API-DMAC7.html)
NZ (1) NZ576420A (cg-RX-API-DMAC7.html)
RU (1) RU2515904C2 (cg-RX-API-DMAC7.html)
TN (1) TN2009000102A1 (cg-RX-API-DMAC7.html)
TW (1) TWI516276B (cg-RX-API-DMAC7.html)
UA (1) UA102812C2 (cg-RX-API-DMAC7.html)
WO (1) WO2008046724A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200902697B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
CU23736A1 (es) * 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
WO2011004899A1 (en) * 2009-07-06 2011-01-13 Takeda Pharmaceutical Company Limited Cancerous disease modifying antibodies
WO2011066417A2 (en) * 2009-11-24 2011-06-03 Carnegie Mellon University Antibodies and conjugates for modulators of angiogenesis
EP3165538A1 (en) 2010-11-03 2017-05-10 Argen-X Nv Anti c-met antibodies
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
EP2773660A2 (en) 2011-11-03 2014-09-10 Argen-X B.V. Chimeric human-camel antigens and their use
CA2904357C (en) 2013-03-15 2020-09-22 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
US10793628B2 (en) 2014-06-30 2020-10-06 Academia Sinica Isolated antibodies against interleukin-17 receptor B (IL-17RB) for cancer therapy
CA2961917A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
TWI740824B (zh) * 2015-04-27 2021-10-01 法商皮爾法伯製藥公司 新穎的igf-1r抗體及其用於癌症診斷之用途(一)
AR105553A1 (es) * 2015-04-27 2017-10-18 Pf Medicament Anticuerpo del receptor del factor 1 del crecimiento similar a insulina (igf-1r) y su utilización para diagnosticar cáncer
CN115925931A (zh) * 2015-08-14 2023-04-07 默沙东公司 抗tigit抗体
RU2722451C1 (ru) * 2015-09-29 2020-06-01 Шанхай Чжанцзян Биотекнолоджи Ко., Лтд. Pd-1 антитела и их применение.
GB2547179A (en) * 2015-10-26 2017-08-16 Quethera Ltd Genetic construct
WO2025111382A2 (en) * 2023-11-21 2025-05-30 Board Of Regents, The University Of Texas System Anti-lamp5 antibodies, engineered immune cells expressing anti-lamp5 antibodies, and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0214640A2 (en) * 1985-09-11 1987-03-18 Japanese Foundation For Cancer Research Monoclonal antibody in relation to drug-resistant cancers and production thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化b−b10
AU668910B2 (en) * 1992-02-06 1996-05-23 Merrell Dow Pharmaceuticals Inc. Reversal of multi-drug resistance by tetraarylethylenes
IT1257893B (it) 1992-06-17 1996-02-16 Ist Superiore Sanita Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteina umana.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5503984A (en) * 1993-04-13 1996-04-02 Health Research, Inc. Hybridoma producing monoclonal antibody F4 which specifically binds to multidrug resistant P-glycoprotein and assays for detection of P-glycoprotein
WO1999066027A1 (en) * 1998-06-15 1999-12-23 The Research Foundation Of State University Of New York Monoclonal antibodies that recognize antigens associated with tumor metastasis
US7303760B2 (en) 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
ES2283759T3 (es) 2002-01-18 2007-11-01 Pierre Fabre Medicament Anticuerpos anti-igf-ir y sus aplicaciones.
US20040121965A1 (en) 2002-09-20 2004-06-24 Wyeth Holdings Corporation Method of treating resistant tumors
US20050142609A1 (en) * 2003-10-08 2005-06-30 Ebioscience Native immunoglobulin binding reagents and methods for making and using same
WO2005077385A2 (en) 2004-02-18 2005-08-25 Gpc Biotech Ag Methods for treating resistant or refractory tumors
EP1742060A1 (en) * 2005-01-24 2007-01-10 DIGILAB BioVisioN GmbH TIF1-beta peptides and nucleic acids for diagnosis and therapy of cancer and colorectal cancerous disorders.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0214640A2 (en) * 1985-09-11 1987-03-18 Japanese Foundation For Cancer Research Monoclonal antibody in relation to drug-resistant cancers and production thereof

Also Published As

Publication number Publication date
IL197790A0 (en) 2011-08-01
US20130028835A1 (en) 2013-01-31
EP2491945B9 (en) 2017-03-08
EP2494984A1 (en) 2012-09-05
US20100146650A1 (en) 2010-06-10
CN101516394A (zh) 2009-08-26
AU2007312437C1 (en) 2014-04-10
FR2906533A1 (fr) 2008-04-04
EP2497491A1 (en) 2012-09-12
NO20091613L (no) 2009-06-26
EP2494984B1 (en) 2017-01-04
EP2081592A1 (en) 2009-07-29
UA102812C2 (ru) 2013-08-27
FR2906533B1 (fr) 2013-02-22
JP2010504743A (ja) 2010-02-18
US8241646B2 (en) 2012-08-14
US8808667B2 (en) 2014-08-19
KR20090057469A (ko) 2009-06-05
WO2008046724A1 (en) 2008-04-24
EP2081592B1 (en) 2016-01-13
BRPI0717246A2 (pt) 2013-10-08
AU2007312437B2 (en) 2014-01-23
RU2009114682A (ru) 2010-11-20
CN101516394B (zh) 2014-07-30
EP2491945A1 (en) 2012-08-29
MA30954B1 (fr) 2009-12-01
TN2009000102A1 (en) 2010-08-19
ZA200902697B (en) 2010-04-28
CA2663561A1 (en) 2008-04-24
AU2007312437A1 (en) 2008-04-24
HK1131063A1 (en) 2010-01-15
NZ576420A (en) 2012-05-25
MX2009003245A (es) 2009-07-07
IL197790A (en) 2016-10-31
AR063061A1 (es) 2008-12-23
EP2497491B1 (en) 2017-03-01
TW200822934A (en) 2008-06-01
EP2491945B1 (en) 2016-12-07
RU2515904C2 (ru) 2014-05-20
TWI516276B (zh) 2016-01-11
JP5774276B2 (ja) 2015-09-09

Similar Documents

Publication Publication Date Title
CN101516394B (zh) 制备抗耐药性抗原的活性抗体的方法、所述方法获得的抗体及其用途
KR102068600B1 (ko) Pdl-1 항체, 그 약학적 조성물 및 그 용도
CN111363041B (zh) 新型抗-pd-l1抗体
CN101535344B (zh) 新型抗增殖抗体
JP2011517565A (ja) 癌の処置に用いられる新規な抗体
CN101528256B (zh) 抗-cd151抗体在治疗癌症中的用途
WO2023118395A1 (en) Treatment paradigm for an anti-cd19 antibody therapy
HK1131063B (en) Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses
CN119136832A (zh) 抗体-药物缀合物与抗-SIRPα抗体的组合
HK40032298A (en) Novel anti-pd-l1 antibodies
HK40032298B (en) Novel anti-pd-l1 antibodies
HK1132904B (en) Use of an anti-cd151 antibody in the treatment of cancer
HK1260737B (en) Novel anti-pd-l1 antibodies
HK1260737A1 (en) Novel anti-pd-l1 antibodies

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20180317

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20180317

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000